Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease

Non-alcoholic Fatty Liver Disease (NAFLD) is the most common form of liver disease and is associated with metabolic dysregulation. Although G protein-coupled receptor 84 (GPR84) has been associated with inflammation, its role in metabolic regulation remains elusive. The aim of our study was to evaluate the potential of PBI-4547 for the treatment of NAFLD and to validate the role of its main target receptor, GPR84. We report that PBI-4547 is a fatty acid mimetic, acting concomitantly as a GPR84 antagonist and GPR40/GPR120 agonist. In a mouse model of diet-induced obesity, PBI-4547 treatment improved metabolic dysregulation, reduced hepatic steatosis, ballooning and NAFLD score. PBI-4547 stimulated fatty acid oxidation and induced gene expression of mitochondrial uncoupling proteins in the liver. Liver metabolomics revealed that PBI-4547 improved metabolic dysregulation induced by a high-fat diet regimen. In Gpr84^−/− mice, PBI-4547 treatment failed to improve various key NAFLD-associated parameters, as was observed in wildtype littermates. Taken together, these results highlight a detrimental role for the GPR84 receptor in the context of meta-inflammation and suggest that GPR84 antagonism via PBI-4547 may reflect a novel treatment approach for NAFLD and its related complications.

Design and Synthesis of New 1,3,5-Trisubstituted Triazines for the Treatment of Cancer and Inflammation

Low-molecular-weight synthetic molecules 1 with the general 2-(fluorophenylamino)-4,6-disubstituted 1,3,5-triazine structure and showing anti-inflammatory and anticancer activities were explored. Structure-activity relationship studies demonstrated the importance of the aminopentyl chain, the 3- or 4-fluorophenylaniline component, and the presence of at least one substituent, such as a tyramine moiety, attached directly to the triazine ring as essential for good activity. These compounds, represented by leads 4-{2-[4-(5-Aminopentylamino)-6-(3-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (6) and 4-{2-[4-(5-Aminopentylamino)-6-(4-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (10), displayed moderate and significant in vitro and in vivo dual activities, respectively, and address the molecular link between inflammation and cancer. Compound 10 demonstrated significant antitumor efficacy upon administration by the oral and intravenous routes in several animal models. This class of triazine compounds is new, safe, and nontoxic and offers a novel approach to the treatment of inflammation and cancer.

PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway

Hepatic fibrosis is a major cause of morbidity and mortality for which there is currently no effective therapy. We previously showed that 2-(3-pentylphenyl)acetic acid (PBI-4050) is a dual G protein-coupled receptor GPR40 agonist/GPR84 antagonist that exerts antifibrotic, anti-inflammatory, and antiproliferative action. We evaluated PBI-4050 for the treatment of liver fibrosis in vivo and elucidated its mechanism of action on human hepatic stellate cells (HSCs). The antifibrotic effect of PBI-4050 was evaluated in carbon tetrachloride (CCl₄)- and bile duct ligation-induced liver fibrosis rodent models. Treatment with PBI-4050 suppressed CCl₄-induced serum aspartate aminotransferase levels, inflammatory marker nitric oxide synthase, epithelial to mesenchymal transition transcription factor Snail, and multiple profibrotic factors. PBI-4050 also decreased GPR84 mRNA expression in CCl₄-induced injury, while restoring peroxisome proliferator-activated receptor γ (PPARγ) to the control level. Collagen deposition and α-smooth muscle actin (α-SMA) protein levels were also attenuated by PBI-4050 treatment in the bile duct ligation rat model. Transforming growth factor-β-activated primary HSCs were used to examine the effect of PBI-4050 and its mechanism of action in vitro. PBI-4050 inhibited HSC proliferation by arresting cells in the G0/G1 cycle phase. Subsequent analysis demonstrated that PBI-4050 signals through a reduction of intracellular ATP levels, activation of liver kinase B1 (LKB1) and AMP-activated protein kinase (AMPK), and blockade of mammalian target of rapamycin (mTOR), resulting in reduced protein and mRNA levels of α-SMA and connective tissue growth factor and restored PPARγ mRNA expression. Our findings suggest that PBI-4050 may exert antifibrotic activity in the liver through a novel mechanism of action involving modulation of intracellular ATP levels and the LKB1/AMPK/mTOR pathway in stellate cells, and PBI-4050 may be a promising agent for treating liver fibrosis.

Abstract 3534: PBI-1402, a first-in-class erythropoiesis regulating agent, possesses differentiation properties and demonstrates synergistic anticancer activity in combination with chemotherapy

Background: PBI-1402 reduces the need for transfusion and increases hemoglobin (Hb) level and red blood cell count (RBC) in chemotherapy-induced anemia (CIA) patients by a mechanism of action which is distinct from erythropoietin (EPO). The PBI-1402 receptor is also expressed on certain cancer cells such as leukemia (K562), lung (LL-2), prostate (PC-3) and pancreas (Panc-02).

Aim: The objective of this study was to determine the role of the PBI-1402 receptor on tumor growth.

Methods: Cell proliferation and differentiation of K562 (human erythroleukemia) was studied in presence of PBI-1402 or EPO using 2,7-diaminofluorene for hemoglobin quantification. The effect of oral administration of PBI-1402 in combination with chemotherapy agents (gemcitabine or cyclophosphamide) was studied in subcutaneous syngeneic Panc02, LL-2 and xenogeneic PC-3 models.

Results: PBI-1402 inhibits proliferation of K562 cells and promotes differentiation of the remaining cells. K562 cells express both EPO and PBI-1402 receptors. EPO increases phosphorylation of ERK1/2 and Stat3 (linked to cell proliferation) while PBI-1402 decreases it in a dose dependent manner. The antitumor efficacy of oral administration of PBI-1402 was studied in combination with gemcitabine in subcutaneous LL2 and Panc02 as well as in orthotopic Panc02 cancers. In subcutaneous Panc02, gemcitabine induced a significant inhibition (p<0.05) of tumor growth from day 27 to 34 with T/C from 55% to 78%. PBI-1402 induced a significant inhibition (p<0.05) of tumor growth from day 23 to 44 with T/C from 26% to 58%. The combination therapy induced a significant (p<0.05) inhibition of tumor growth and T/C<40% from day 23 to 37 when compared to control and at day 23, 25 and 30 to 39 when compared to gemcitabine alone. In orthotopic Panc02, mice treated with gemcitabine or a combination of gemcitabine and PBI-1402 displayed prolonged survival (71 and 88 days, respectively) compared to control (48 days). In LL-2 cancer, at day 25, mice treated with PBI-1402 or gemcitabine alone had a T/C of 94% and 72%, respectively. Mice treated with a combination of gemcitabine plus PBI-1402 displayed a significant (synergistic) reduction of tumor growth (T/C: 33%). The effect of PBI-1402 alone or in combination with cyclophosphamide was also studied in a xenograft prostate PC-3 tumor. Mice treated with PBI-1402 or cyclophosphamide alone have a significant T/C<40% from day 21 to 56 and day 35 to 56, respectively. Mice treated with a combination of cyclophosphamide plus PBI-1402 displayed tumor regression from day 21 to 56.

Conclusion: These results suggest that PBI-1402 has the potential to inhibit the growth of lung, prostate and pancreatic cancer by induction of cell differentiation. PBI-1402-differentiated cancer cells appear to be more susceptible to chemotherapeutic agents.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3534. doi:10.1158/1538-7445.AM2011-3534

Mapping of quantitative trait loci for field resistance to Fusarium head blight in an European winter wheat

Fusarium head blight (FHB) caused by Fusarium culmorum is an economically important disease of wheat that may cause serious yield and quality losses under favorable climate conditions. The development of disease-resistant cultivars is the most effective control strategy. Worldwide, there is heavy reliance on the resistance pool originating from Asian wheats, but excellent field resistance has also been observed among European winter wheats. The objective of this study was to map and characterize quantitative traits loci (QTL) of resistance to FHB among European winter wheats. A population of 194 recombinant inbred lines (RILs) was genotyped from a cross between two winter wheats Renan (resistant)/Récital (susceptible) with microsatellites, AFLP and RFLP markers. RILs were assessed under field conditions For 3 years in one location. Nine QTLs were detected, and together they explained 30-45% of the variance, depending on the year. Three of the QTLs were stable over the 3 years. One stable QTL, QFhs.inra.2b, was mapped to chromosome 2B and two QTLs QFhs.inra.5a2 and QFhs.inra5a3, to chromosome 5A; each of these QTLs explained 6.9-18.6% of the variance. Other QTLs were identified on chromosome 2A, 3A, 3B, 5D, and 6D, but these had a smaller effect on FHB resistance. One of the two QTLs on chromosome 5A was linked to gene B1 controlling the presence of awns. Overlapping QTLs for FHB resistance were those for plant height or/and flowering time. Our results confirm that wheat chromosomes 2A, 3A, 3B, and 5A carry FHB resistance genes, and new resistance factors were identified on chromosome arms 2BS and 5AL. Markers flanking these QTLs should be useful tools for combining the resistance to FHB of Asian and European wheats to increase the resistance level of cultivars.

Study of the relationship between pre-harvest sprouting and grain color by quantitative trait loci analysis in a whitexred grain bread-wheat cross

In many wheat ( Triticum aestivumL.) growing areas, pre-harvest sprouting (PHS) may cause important damage, and in particular, it has deleterious effects on bread-making quality. The relationship between PHS and grain color is well known and could be due either to the pleiotropic effect of genes controlling red-testa pigmentation ( R) or to linkage between these genes and other genes affecting PHS. In the present work, we have studied a population of 194 recombinant inbred lines from the cross between two cultivars, 'Renan' and 'Récital', in order to detect QTLs for both PHS resistance and grain color. The variety 'Renan' has red kernels and is resistant to PHS, while 'Récital' has white grain and is highly susceptible to PHS. A molecular-marker linkage map of this cross was constructed using SSRs, RFLPs and AFLPs. The population was evaluated over 2 years at Clermont-Ferrand (France). PHS was evaluated on mature spikes under controlled conditions and red-grain color was measured using a chromameter. Over the 2 years, we detected four QTLs for PHS, all of them being co-localized with QTLs for grain color. Three of them were located on the long arm of chromosomes 3 A, 3B and 3D, close to the loci where the genes R and taVp1 were previously mapped. For these three QTLs, the resistance to PHS is due to the allele of the variety 'Renan'. Another co-located QTL for PHS and grain color was detected on the short arm of chromosome 5 A. The resistance for PHS for this QTL is due to the allele of 'Récital'.

Efficiency of RFLP, RAPD, and AFLP markers for the construction of an intraspecific map of the tomato genome

We have constructed a tomato genetic linkage map based on an intraspecific cross between two inbred lines of Lycopersicon esculentum and L. esculentum var. cerasiforme. The segregating population was composed of 153 recombinant inbred lines. This map is comprised of one morphological, 132 RFLP (restriction fragment length polymorphism, including 16 known-function genes), 33 RAPD (random amplified polymorphic DNA), and 211 AFLP (amplified fragment length polymorphism) loci. We compared the 3 types of markers for their polymorphism, segregation, and distribution over the genome. RFLP, RAPD, and AFLP methods revealed 8.7%, 15.8%, and 14.5% informative bands, respectively. This corresponded to polymorphism in 30% of RFLP probes, 32% of RAPD primers, and 100% of AFLP primer combinations. Less deviation from the 1:1 expected ratio was obtained with RFLP than with AFLP loci (8% and 18%, respectively). RAPD and AFLP markers were not randomly distributed over the genome. Most of them (60% and 80%, respectively) were grouped in clusters located around putative centromeric regions. This intraspecific map spans 965 cM with an average distance of 8.3 cM between markers (of the framework map). It was compared to other published interspecific maps of tomato. Despite the intraspecific origin of this map, it did not show any increase in length when compared to the high-density interspecific map of tomato.

Presence of cadmium in the saliva of adult male workers

Samples of mixed saliva were collected from 16 workers exposed to cadmium dusts and fumes and 19 unexposed co-workers. Samples of total blood and plasma were also obtained. Cadmium (Cd) was measured by flameless atomic absorption spectrometry. Cd was found in higher concentrations in saliva than in blood. The concentration of Cd in saliva was markedly elevated in exposed subjects; the difference was less important in blood. Smokers had more Cd in their blood than non-smokers, but this was not the case for saliva. In vitro studies measuring uptake of Cd by slices of rat submaxillary gland indicated that movement of the metal occurs passively.

[Group dynamics in psychiatric residents]

For many years group dynamics or group psychotherapy has been used in training of psychiatric residents. An attempt is made to define the specific learning problems facing these residents.

The needs of the resident can be met in many ways, but the participation in a group seems to be particularly meaningful. Three stages are described during the group process:

1) The period of euphoria, which coincides with the beginning of the training and only lasts a few months. This is when the resident toys with new words, new concepts and there is a magical connotation to all of this.

2) A depressive period, when the resident begins to ‘feel’ his many difficulties in dealing with patients. He also has to face the many psychiatric ideologies confronting him and he finds it impossible to have a total theoretical grasp of the psychiatric knowledge. This situation creates a good deal of anxiety and it is particularly during this phase that group dynamics can be useful.

3) A period of adaptation. Adaptation is used here as it is put forward by the ego psychologists, that is, as being an active process.

Finally an analogy is drawn between the maturation and learning taking place in the psychiatric resident and the adolescent's search for identity and the use of group dynamics as a valuable tool in this on-going process.